Grade My Investments
HomeFree Stock Grades › INVA

Innoviva, Inc. (INVA) Stock Grade

INVA · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$1.3B
P/E Ratio
5.0
Revenue Growth (YoY)
+18.5%
Net Margin
63.8%
Return on Equity
23.1%
Dividend Yield
None

About Innoviva, Inc.'s fundamentals

Innoviva is a biotech company with a $1.3 billion market capitalization that demonstrates strong profitability metrics, including a net margin of 63.8% and a return on equity of 23.1%. The company is growing revenues at an 18.5% year-over-year rate while trading at a P/E ratio of 5.0, suggesting a relatively low valuation relative to earnings. With no dividend payment, the company appears to be reinvesting profits into operations or maintaining cash reserves rather than returning capital to shareholders.

Track INVA free — no credit card required. Live grade + monthly AI report →